Coronavirus company news summary – Iraq authorises AstraZeneca/University of Oxford and Sinopharma’s vaccines – Russia reports its second Covid-19 vaccine is 100% effective in Phase I and II studies

20 January 2021 (Last Updated January 20th, 2021 08:50)

20 January 2021

InVixa has entered into an exclusive licensing deal with the University of California, Davis, for commercialising inhaled statins to treat the SARS-CoV-2 virus. The deal allows InVixa the exclusive rights to commercialise its inhaled product for Covid-19 and other viral respiratory diseases.

Iraq‘s national authority for drug selection has approved UK’s AstraZeneca/University of Oxford and China’s Sinopharm Covid-19 vaccines for emergency use in the country. In late December, the Iraqi drug authority granted emergency authorisation to the Pfizer/BioNTech vaccine, with the first batch of the vaccine scheduled to arrive in February 2021.

Algernon Pharmaceuticals announced that the external Data and Safety Monitoring Board (DSMB) has reviewed the Phase 2b part of the company’s Phase 2b/3 human study of Ifenprodil (NP-120) for treating Covid-19. As a result, the board granted the company approval to continue with the Phase 3 part of its clinical study.

Rospotrebnadzor, Russia’s federal agency for consumer rights protection and wellbeing, announced that Russia’s second Covid-19 vaccine candidate EpiVacCorona proved to be 100% effective in its early-stage trials. The data of the Phase I and II trials were released before the commencement of the Phase III trial, which is scheduled to involve large number of participants and a placebo group.